Associations between lifetime classic psychedelic use and cardiometabolic diseases

This observational survey study (n=752.374) investigated the relationship between lifetime classic psychedelic use and cardiometabolic diseases and found that lifetime classic psychedelic use was associated with a 23% lower odds of heart disease and a 12% lower odds of diabetes in the past year.

Abstract

Introduction: The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases.

Methods: Using data from the National Survey on Drug Use and Health (2005-2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes.

Results: Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65-0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78-0.99), p = .036).

Discussion: Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.”

Authors: Otto Simonsson, Walter Osika, Robin L. Carhart-Harris & Peter S. Hendricks

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account

Study details

Compounds studied
DMT Psilocybin LSD Ayahuasca

Topics studied
Immunity

Study characteristics
Observational Survey

Participants
752374

Authors

Authors associated with this publication with profiles on Blossom

Robin Carhart-Harris
Dr. Robin Carhart-Harris is the Founding Director of the Neuroscape Psychedelics Division at UCSF. Previously he led the Psychedelic group at Imperial College London.

0 Comments
Inline Feedbacks
View all comments